Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Cejka, V; Riepl, H; Schwegel, N; Kolesnik, E; Zach, D; Santner, V; Höller, V; Schweighofer, N; Obermayer-Pietsch, B; Pieber, T; Morbach, C; Frantz, S; Zirlik, A; von, Lewinski, D; Störk, S; Posch, F; Ablasser, K; Verheyen, N.
Prognostic impact of gait speed, muscle strength and muscle mass in chronic heart failure-A prospective cohort study.
ESC Heart Fail. 2025; 12(3):2113-2124 Doi: 10.1002/ehf2.15221 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Verheyen Nicolas Dominik
Co-authors Med Uni Graz: Ablasser Klemens; Höller Viktoria; Kolesnik Ewald; Obermayer-Pietsch Barbara; Pieber Thomas; Posch Florian; Riepl Hermann Stefan; Santner Viktoria; Schwegel Nora; Schweighofer Natascha; von Lewinski Dirk; Zach David; Zirlik Andreas
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: AIMS: Heart failure (HF) impairs skeletal muscle mass and function, which contributes to reduced physical performance. We investigated the prognostic impact of gait speed (GS), handgrip strength (HG) and appendicular skeletal muscle index (ASMI) on cardiovascular outcomes in a prospective HF cohort. METHODS: This single-centre prospective cohort study included adults with stable chronic HF with a previous diagnosis of overtly reduced left ventricular ejection fraction (LVEF) <40% and LVEF < 50% at enrolment. GS was measured by the 4 m GS test, maximal HG was measured with a hydraulic dynamometer, and ASMI was measured by dual-energy X-ray absorptiometry. The primary combined outcome was cardiovascular death or worsening HF. Fine and Gray regression models were calculated, treating non-cardiovascular death as the competing event. RESULTS: Two hundred five patients (78% male) were analysed. The median age was 66 (quartiles: 58-74) years, 31% had diabetes mellitus, and the median LVEF was 37 (30-43) %. Median GS was 1.0 (0.8-1.0) m/s, median HG was 32 (24-40) kg, and median ASMI was 8.0 (7.2-8.9) kg/m². During a median follow-up of 4.7 (4.0-5.3) years, the primary outcome was observed in 52 patients. In models adjusted for key clinical covariates, lower GS predicted a higher risk of cardiovascular death or worsening HF [subdistribution hazard ratio (SHR) per 0.1 m/s increase = 0.81, 95% confidence interval (CI) 0.68-0.95], whereas HG (SHR per 5 kg increase = 0.97, 95% CI 0.84-1.10) and ASMI (SHR per 1 kg/m² increase = 1.17, 95% CI 0.94-1.44) did not. In the analysis of effect modification, these associations were consistent across key clinical subgroups. CONCLUSIONS: Higher GS was independently associated with a lower risk of cardiovascular death or worsening HF, whereas HG and ASMI were not. We prospectively confirm GS as a physical performance measure with clear prognostic significance for patients with HF.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Male - administration & dosage; Female - administration & dosage; Heart Failure - physiopathology, diagnosis; Prospective Studies - administration & dosage; Middle Aged - administration & dosage; Prognosis - administration & dosage; Aged - administration & dosage; Walking Speed - physiology; Muscle, Skeletal - physiopathology, diagnostic imaging; Muscle Strength - physiology; Stroke Volume - physiology; Chronic Disease - administration & dosage; Follow-Up Studies - administration & dosage; Ventricular Function, Left - physiology; Hand Strength - physiology
Find related publications in this database (Keywords): ASMI; cardiovascular outcome; gait speed; handgrip; heart failure; prognostic impact